RxDoctor Payments Data

Melanie Schlittenhardt, NP

Nurse Practitioner · Bismarck, NDNPI 1174561617

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,006 of the $1,184 with a category attached, or 85.0%. Medtronic accounts for 61.6% of it on its own, with 6 other manufacturers making up the rest.

$1,184in general payments, 2019–2025

Across 31 payments — averaging $38.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$730
  • Astellas Pharma US Inc$288
  • Coloplast$62
  • Axonics, Inc.$62
  • Johnson & Johnson$15
  • AbbVie$14
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$1,00685%
  • Education$17815%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,184 in reported general payments places this provider in the 85th percentile of 455 nurse practitioner providers in North Dakota.

See all nurse practitioner providers in North Dakota

Medicare billing

Part B allowed, 2024
$64,000
Medicare patients
237
Services billed
757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron84$44,595
GemtesaVibegron99$39,061
Estradiol93$9,645
LinzessLinaclotide12$6,532
Trospium Chloride110$5,505
Solifenacin Succinate169$3,598
Methenamine Hippurate39$2,867
Fesoterodine Fumarate ErFesoterodine Fumarate32$2,362
Fluconazole17$181
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim19$153
Oxybutynin Chloride ErOxybutynin Chloride17$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$288$44,59584 claims
AbbVieLinzess$14$6,53212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 455 nurse practitioner providers in North Dakota.

Other nurse practitioner in Bismarck

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →